These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38310879)

  • 1. Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event.
    Kim HJ; Kim BS; Lee Y; Ahn SB; Kim DW; Shin JH
    Diabetes Metab J; 2024 May; 48(3):449-462. PubMed ID: 38310879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study.
    Kim JH; Moon JS; Byun SJ; Lee JH; Kang DR; Sung KC; Kim JY; Huh JH
    Cardiovasc Diabetol; 2020 May; 19(1):51. PubMed ID: 32359355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults.
    Lee JH; Park K; Lee HS; Park HK; Han JH; Ahn SB
    Clin Mol Hepatol; 2022 Oct; 28(4):814-826. PubMed ID: 35680169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.
    Colantoni A; Bucci T; Cocomello N; Angelico F; Ettorre E; Pastori D; Lip GYH; Del Ben M; Baratta F
    Cardiovasc Diabetol; 2024 May; 23(1):175. PubMed ID: 38769519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study.
    Cai X; Gao J; Hu J; Wen W; Zhu Q; Wang M; Liu S; Hong J; Wu T; Yang S; Tuerxun G; Li N
    Dis Markers; 2022; 2022():4930355. PubMed ID: 35251371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.
    Hagström H; Talbäck M; Andreasson A; Walldius G; Hammar N
    Gastroenterology; 2020 Jan; 158(1):200-214. PubMed ID: 31563624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).
    Saokaew S; Kanchanasuwan S; Apisarnthanarak P; Charoensak A; Charatcharoenwitthaya P; Phisalprapa P; Chaiyakunapruk N
    Liver Int; 2017 Oct; 37(10):1535-1543. PubMed ID: 28294515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients.
    Bockarie AS; Nartey YA; Nsiah P; Edzie EKM; Tuoyire D; Acquah S; Eliason S; Nkum B
    Endocrinol Diabetes Metab; 2023 Nov; 6(6):e456. PubMed ID: 37814510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the optimal cut-off values of anthropometric indices for predicting metabolic syndrome and carotid intima-medial thickness in a Korean population.
    Yang YJ; Park HJ; Won KB; Chang HJ; Park GM; Kim YG; Ann SH; Park EJ; Kim SJ; Lee SG
    Medicine (Baltimore); 2019 Oct; 98(42):e17620. PubMed ID: 31626142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome.
    Kositamongkol C; Charernboon T; Chaisathaphol T; Washirasaksiri C; Auesomwang C; Sitasuwan T; Charatcharoenwitthaya P; Phisalprapa P
    Medicine (Baltimore); 2021 Nov; 100(44):e27640. PubMed ID: 34871234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study.
    Lin A; Wong ND; Razipour A; McElhinney PA; Commandeur F; Cadet SJ; Gransar H; Chen X; Cantu S; Miller RJH; Nerlekar N; Wong DTL; Slomka PJ; Rozanski A; Tamarappoo BK; Berman DS; Dey D
    Cardiovasc Diabetol; 2021 Jan; 20(1):27. PubMed ID: 33514365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients.
    Saokaew S; Kositamongkol C; Charatcharoenwitthaya P; Srivanichakorn W; Washirasaksiri C; Chaiyakunapruk N; Phisalprapa P
    Medicine (Baltimore); 2020 Dec; 99(50):e23619. PubMed ID: 33327335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
    Lee JH; Kwon YJ; Park K; Lee HS; Park HK; Han JH; Ahn SB
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.